癌の治療決定の遺伝的根拠について
Janet E Dancey1, Philippe L Bedard, Nicole Onetto
1Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
Cell
|February 7, 2012
まとめ
パーソナライズされたがん医学は,癌の変異を標的とした遺伝的知識を使用して,治療を推測から証拠に基づいた決定に移行します. この枠組みは,がん患者の治療結果を改善するために極めて重要です.
科学分野:
- 腫瘍学 腫瘍学
- ゲノミクスゲノミクスとは
- 翻訳医学は翻訳医学である.
背景:
- パーソナライズされたがん医学は,がんの遺伝子変異と標的治療を理解することに依存しています.
- 癌の遺伝学,技術,薬の開発の進歩は,新しい臨床的枠組みの機会を生み出しています.
研究 の 目的:
- パーソナライズされたがん医療のための臨床試験と研究枠組みを確立する.
- 癌治療の意思決定をヒューリスティックなアプローチから,エビデンスに基づく戦略へと移行させる.
主な方法:
- ガン治療の意思決定プロセスにゲノム検査の統合.
- パーソナライズされた腫瘍学の臨床試験と研究のための枠組みの開発.
主要な成果:
- この研究は,パーソナライズされたがん医療のための構造化された枠組みの必要性と可能性を概説しています.
- パーソナライズされたアプローチを推進する科学的および倫理的な必要性を強調します.
結論:
- パーソナライズされたがん医療の完全な利点を実現するために,堅牢な枠組みの実施は不可欠です.
- ゲノム検査の統合における課題に取り組むことは,がん患者のアウトカムを改善するための鍵です.
関連する概念動画
Cancer
51.8K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.8K
Cancer Prevention
6.5K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.5K
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Cancer Survival Analysis
870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870


